Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

著者: Susan O’Brien, Jeffrey A. Jones, Steven Coutré, Anthony R. Mato, Peter Hillmen, Constantine S. Tam, Anders Österborg, Tanya Siddiqi, Michael J. Thirman, Richard R. Furman, Osman İlhan, Michael J. Keating, Timothy G. Call, Jennifer R. Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F. James, Alvina D. Chu, Michael Hallek, Stephan Stilgenbauer - The Lancet 2016 被引用: 339